

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**Date of Report:** February 25, 2019  
**Commission File Number:** 001-36891

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

**8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**EXHIBIT INDEX**

**Exhibit**

**Title**

[99.1](#)

[Press release, dated February 25, 2019](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**

(Registrant)

February 25, 2019

By: /s/ André Choulika

André Choulika

Chief Executive Officer

**Collectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry**

***Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators***

NEW YORK--(BUSINESS WIRE)--February 25, 2019--Regulatory News:

Collectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on allogeneic gene edited CAR T-cells (UCART), today announced the publication of a study in *The Journal of Biological Chemistry*, identifying Granulocyte Macrophage Colony Stimulating Factor (GMCSF) secreted by Chimeric Antigen Receptor (CAR) T-cells as a key factor promoting cytokine release syndrome (CRS). The accelerated report leverages these findings to elaborate an innovative engineering strategy that paves the way for developing safer UCART products.

Utilizing these results, Collectis developed engineered GMCSF Knock-Out CAR T-cells through TALEN<sup>®</sup>-mediated gene inactivation. The inactivation of GMCSF in CAR T-cells was found to prevent secretion of pro-inflammatory cytokines by monocytes, without compromising CAR T-cell anti-tumor activity.

“CAR T-cells have achieved high rates of complete remission in hematological malignancies, however, this 'living drug' can show life-threatening inflammatory side effects including CRS and neurotoxicity that need to be addressed,” said Mohit Sachdeva, Ph.D., Innovation Project Leader at Collectis. “Our engineering strategy circumvents such toxic side effects and propose safer, equally potent UCART-cells, to improve patients’ quality of life during treatment.”

“Today, tocilizumab or glucocorticoid treatments are considered the standard of care for CRS management,” added Julien Valton, Ph.D., Innovation Team Leader at Collectis. “However, these treatments increase patient medication burden, add substantial costs and lengthen treatment time in intense care settings. To overcome these clinical challenges, we investigated the biogenesis of CRS and based on our findings, developed a CAR T-cell product candidate that could potentially prevent rather than treat CRS symptoms. We hope this approach can bypass CRS symptomatic treatments and improve the overall safety of CAR T-cell therapies for cancer patients.”

**Julien Valton, Ph.D., Innovation Team Leader, Cellular Engineering & Adoptive CAR T-Cell Immunotherapy**

Dr. Julien Valton obtained his Ph.D. at the University Joseph Fourier in Grenoble, France, where he was trained as an enzymologist. He then joined the Yale School of Medicine to apply his knowledge to therapeutic research by investigating the mechanism of inhibition of receptor tyrosine kinases that are involved in the development of gastrointestinal cancer. In 2009, he moved a step further into the field of applied science by joining the Innovation Department of Collectis, where he actively participated in using and improving TALEN<sup>®</sup> gene editing technology for targeted gene therapy and genome engineering. He is now using TALEN<sup>®</sup> along with protein engineering techniques to develop the next-generation CAR T-cells to treat different malignancies.

---

## **Mohit Sachdeva, Ph.D., Innovation Team Senior Scientist**

Dr. Sachdeva is an experienced cancer biologist with expertise in immuno-oncology, having authored/co-authored approximately 20 manuscripts in peer-reviewed journals throughout his career. During his time at Collectis, he has been studying pathways that could be exploited to engineer potent, yet safer, CAR T-cells using gene editing and targeted integration technologies. After receiving his Ph.D. at Southern Illinois University, he completed a successful post-doc at Duke University.

### **Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators**

**Mohit Sachdeva<sup>1\*</sup>, Philippe Duchateau<sup>2</sup>, Stéphane Depil<sup>2</sup>, Laurent Poirot<sup>2</sup> and Julien Valton<sup>1\*</sup>**

<sup>1</sup>*Collectis, Inc., 430 East 29th Street, New York, NY 10016, USA*

<sup>2</sup>*Collectis, 8 rue de la Croix Jarry, 75013 Paris, France*

#### **About Collectis**

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 19 years of expertise in gene editing – built on its flagship TALEN<sup>®</sup> technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it. TALEN<sup>®</sup> is a registered trademark owned by Collectis.

---

**Disclaimer**

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risk factors that may affect company business and financial performance is included in Collectis’ Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2017 and subsequent filings Collectis makes with the Securities Exchange Commission from time to time. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

**CONTACT:****Media:**

Jennifer Moore, VP of Communications, 917-580-1088, [media@collectis.com](mailto:media@collectis.com)

Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

**IR:**

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)